Skip to main content
. Author manuscript; available in PMC: 2017 May 17.
Published in final edited form as: Ann Epidemiol. 2015 Aug 19;25(11):803–810. doi: 10.1016/j.annepidem.2015.08.002

Table 3.

Hazard ratio estimates of relationships of lympho-hematapoietic neoplasms with insecticide pet treatments1

NHL DLBCL FL CLL/SLL Plasma cell neoplasms Myeloid leukemia
N HR, 95% CI N HR, 95% CI N HR, 95% CI N HR, 95% CI N HR, 95% CI N HR, 95% CI
Lived with pets compared to living with no pets
Never lived with pet 132 Ref 29 Ref 27 Ref 23 Ref 28 Ref 13 Ref
Never treated pets 108 1.04, 0.80–1.34 22 0.99, 0.57–1.74 19 0.88, 0.49–1.60 19 1.04, 0.56–1.93 14 0.65, 0.34–1.25 16 1.52, 0.73–3.20
Ever treated pets 507 1.12, 0.92–1.36 114 1.19, 0.78–1.80 70 0.72, 0.45–1.13 113 1.32, 0.83–2.08 96 1.09, 0.71–1.69 70 1.48, 0.81–2.70
Lived with treated pets compared to living with untreated pets
Lived with untreated pet 108 Ref 22 Ref 19 Ref 19 Ref 14 Ref 16 Ref
Lived with treated pet 507 1.07,0.86–1.32 114 1.19, 0.75–1.89 70 0.80, 0.48–1.34 113 1.25, 0.76–2.05 96 1.71, 0.96–3.01 70 0.95, 0.55–1.66
Ever used flea or tick collar
Lived with untreated pet 208 Ref 47 Ref 35 Ref 40 Ref 33 Ref 34 Ref
Lived with treated pet 407 1.07, 0.90–1.27 89 1.05, 0.73–1.50 54 0.83, 0.54–1.28 92 1.23, 0.84–1.79 77 1.33, 0.88–2.01 52 0.80, 0.52–1.24
Ever use flea spray or powder
Lived with untreated pet 324 Ref 69 Ref 40 Ref 75 Ref 56 Ref 53 Ref
Lived with treated pet 291 1.20, 1.02–1.41 67 1.33, 0.94–1.87 49 1.62, 1.06–2.48 57 0.93, 0.66–1.32 54 1.36, 0.93–1.98 33 0.80, 0.52–1.25
Ever used flea dip
Lived with untreated pet 460 Ref 102 Ref 63 Ref 95 Ref 81 Ref 71 Ref
Lived with treated pet 155 1.11, 0.92–1.34 34 1.11, 0.74–1.65 26 1.33, 0.83–2.14 37 1.13, 0.76–1.67 29 1.30, 0.84–2.01 15 0.66, 0.37–1.16

Abbreviations: NHL, non Hodgkin lymphoma; DLBCL, Diffuse large B cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma

1

Each exposure variable was entered into the model individually. The baseline hazard functions were stratified by age at baseline and a time varying indicator for extension study participation. All models were adjusted for age, race/ethnicity, educational level, United States region of residence, occupational type, body mass index and smoking status.